New investor Credit Suisse Asset Management led the round and all existing preferred equity investors participated. All proceeds will help the company’s sales and marketing infrastructure grow.
Lanx’s device portfolio focuses on minimally invasive spine fusion solutions throughout the U.S., Mexico and Europe.
More Articles on Devices:
A Model for Clinical, Financial Success in Orthopedics
MAKO Surgical Reports 26% Q1 Revenue Increase, MAKOplasty Surgeries Up 30%
Globus Medical Launches New Spinal Surgery System
